• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress

    2/13/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALNY alert in real time by email

    − Achieved Fourth Quarter and Full Year 2024 Global Net Product Revenues of $451 Million and $1,646 Million, Respectively, Representing 30% and 33% Growth Compared to Same Periods in 2023 –

    − Supplemental NDA for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy Accepted by FDA, with March 23, 2025 PDUFA Date –

    − Reiterates Product Sales and Profitability Guidance and Provides Additional 2025 Financial Guidance –

    − Company to Host and Webcast R&D Day on February 25, 2025 –

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2024 and reviewed recent business highlights.

    "2024 was another year of impressive execution for Alnylam, generating product revenues of over $1.6 billion, reflecting growth of 33% compared to 2023, and highlighting the strength of our base business in hATTR-PN and Rare in both the U.S. and international markets. We look forward to potential global launches of vutrisiran in ATTR-CM this year, which will mark an inflection point for our TTR franchise and put us on a path to achieve the financial guidance we've provided," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "Furthermore, driven by our proven RNAi platform, we anticipate 2025 will bring major advancements in our pipeline and expect to have over 25 high-value programs in the clinic across diverse indications by the end of the year. We've seen a remarkable pace of progress toward our Alnylam P5x25 goals and believe we are well positioned for the next half of the decade to continue delivering sustainable innovation to patients."

    Fourth Quarter 2024 and Recent Significant Business Highlights

    Commercial Performance

    Total TTR: ONPATTRO® (patisiran) & AMVUTTRA® (vutrisiran)

    • Achieved global net product revenues for ONPATTRO and AMVUTTRA for the fourth quarter of $56 million and $287 million, respectively, and $343 million combined, representing 35% total TTR growth compared to Q4 2023, and full year 2024 revenues of $253 million and $970 million, respectively, and $1,223 million combined, representing 34% total TTR growth compared to full year 2023.

    Total Rare: GIVLAARI® (givosiran) & OXLUMO® (lumasiran)

    • Achieved global net product revenues for GIVLAARI and OXLUMO for the fourth quarter of $65 million and $44 million, respectively, and $108 million combined, representing 18% total Rare growth compared to Q4 2023, and full year 2024 revenues of $256 million and $167 million, respectively, and $423 million combined, representing 29% total Rare growth compared to full year 2023.

    R&D Highlights

    • Submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) using a Priority Review Voucher for vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy. Parallel filings for regulatory approval have also been submitted in all major regions, including Europe and Japan.
      • The FDA has accepted the sNDA and set an action goal date of March 23, 2025, under the Prescription Drug User Fee Act (PDUFA).
    • Received United States Food & Drug Administration (FDA) Orphan Drug Designation for nucresiran (ALN-TTRsc04) and announced positive interim Phase 1 data in patients with ATTR amyloidosis.
    • Announced positive initial results from the multiple dose portion of the Phase 1 study of mivelsiran in patients with Alzheimer's disease.
    • Initiated a Phase 1 study of ALN-HTT02 in adult patients with Huntington's disease.
    • Completed enrollment in the KARDIA-3 Phase 2 study of zilebesiran, and initiated a Phase 1 study of zilebesiran + REVERSIR for hypertension.
    • Initiated Phase 1 studies of ALN-6400 for a bleeding disorder, and ALN-4324 for type 2 diabetes mellitus.
    • Alnylam's partner, Regeneron Pharmaceuticals, reported positive updated Phase 3 data from an exploratory cohort in the ACCESS-1 trial investigating its first-in-class pozelimab and cemdisiran combination treatment compared to standard-of-care ravulizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) at the American Society of Hematology 2024 Annual Meeting.

    Upcoming Events

    Alnylam will host an R&D Day on February 25, 2025 at 9:00 am ET in New York City. This event, which will be webcast live on the Investors section of the Company's website, www.alnylam.com, will showcase Alnylam's robust pipeline comprising numerous multi-billion-dollar opportunities and highlight RNAi platform innovation driving the next era of growth. A replay will be available on the Company's website within 48 hours after the event.

    The PDUFA target action date for the sNDA for vutrisiran is March 23, 2025.

    Alnylam intends to initiate a Phase 3 study of nucresiran in patients with ATTR amyloidosis with cardiomyopathy in the first half of 2025.

    The PDUFA target action date for fitusiran, an investigational RNAi therapeutic in development for the treatment of hemophilia A and B, with or without inhibitors, is March 28, 2025. Fitusiran is being advanced by Alnylam's partner Sanofi. Assuming approval, Alnylam is eligible to receive tiered royalties of between 15 and 30 percent on global net sales of fitusiran.

    Alnylam's partner, Vir Biotechnology, expects to initiate a Phase 3 chronic hepatitis delta registrational study of elebsiran and to report functional cure results from a Phase 2 chronic hepatitis B study of elebsiran in 2025.

    Financial Highlights for the Fourth Quarter and Year End 2024

     

    Three Months Ended

    December 31,

     

    Twelve Months Ended

    December 31,

    (In thousands)

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Net product revenues

    $

    450,831

     

     

    $

    346,288

     

     

    $

    1,646,228

     

     

    $

    1,241,474

     

    Net revenues from collaborations

     

    106,948

     

     

     

    76,407

     

     

     

    510,221

     

     

     

    546,185

     

    Royalty revenue

     

    35,387

     

     

     

    17,023

     

     

     

    91,794

     

     

     

    40,633

     

    Total revenues

     

    593,166

     

     

     

    439,718

     

     

     

    2,248,243

     

     

     

    1,828,292

     

     

     

     

     

     

     

     

     

    Total operating costs and expenses

     

    698,325

     

     

     

    556,122

     

     

     

    2,425,128

     

     

     

    2,110,467

     

    Loss from operations

     

    (105,159

    )

     

     

    (116,404

    )

     

     

    (176,885

    )

     

     

    (282,175

    )

    Total other expense, net

     

    (88,799

    )

     

     

    (21,283

    )

     

     

    (200,490

    )

     

     

    (151,342

    )

    Benefit from (provision for) income taxes

     

    110,195

     

     

     

    (183

    )

     

     

    99,218

     

     

     

    (6,725

    )

    Net loss

    $

    (83,763

    )

     

    $

    (137,870

    )

     

    $

    (278,157

    )

     

    $

    (440,242

    )

     

     

     

     

     

     

     

     

    Non-GAAP Operating (loss) income*

    $

    (13,514

    )

     

    $

    (74,410

    )

     

    $

    95,199

     

     

    $

    (60,495

    )

     

     

     

     

     

     

     

     

    Non-GAAP Net income (loss)*

    $

    8,048

     

     

    $

    (96,643

    )

     

    $

    (3,051

    )

     

    $

    (201,618

    )

    *For an explanation of our use of non-GAAP financial measures refer to the "Use of Non-GAAP Financial Measures" section later in this press release and for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measures, see the table at the end of this press release.

    Net Product Revenues

     

    Three Months Ended

    December 31,

     

    Twelve Months Ended

    December 31,

    (In thousands)

     

    2024

     

     

    2023

     

     

    2024

     

     

    2023

    ONPATTRO net product revenues

    $

    56,103

     

    $

    79,006

     

    $

    252,857

     

    $

    354,546

    AMVUTTRA net product revenues

     

    286,510

     

     

    175,254

     

     

    970,450

     

     

    557,838

    Total TTR net product revenues

     

    342,613

     

     

    254,260

     

     

    1,223,307

     

     

    912,384

     

     

     

     

     

     

     

     

    GIVLAARI net product revenues

     

    64,645

     

     

    59,298

     

     

    255,871

     

     

    219,251

    OXLUMO net product revenues

     

    43,573

     

     

    32,730

     

     

    167,050

     

     

    109,839

    Total Rare net product revenues

     

    108,218

     

     

    92,028

     

     

    422,921

     

     

    329,090

     

     

     

     

     

     

     

     

    Total net product revenues

    $

    450,831

     

    $

    346,288

     

    $

    1,646,228

     

    $

    1,241,474

    Year over Year % Growth

     

    Three Months Ended

    December 31, 2024

     

    Twelve Months Ended

    December 31, 2024

     

    As Reported

     

    At CER*

     

    As Reported

     

    At CER*

    Total TTR net product revenues

    35

    %

     

    34

    %

     

    34

    %

     

    34

    %

     

     

     

     

     

     

     

     

    Total Rare net product revenues

    18

    %

     

    17

    %

     

    29

    %

     

    28

    %

     

     

     

     

     

     

     

     

    Total net product revenues

    30

    %

     

    29

    %

     

    33

    %

     

    33

    %

     

    * CER = Constant Exchange Rate, representing growth calculated as if the exchange rates had remained unchanged from those used in 2023. CER is a non-GAAP measure. For an explanation of our use of non-GAAP financial measures refer to the "Use of Non-GAAP Financial Measures" section later in this press release and for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measures, see the table at the end of this press release.

    • Net product revenues increased 30% and 33% at actual currency during the three and twelve months ended December 31, 2024, respectively, compared to the same periods in 2023, and 29% and 33% at CER, respectively. The increases are primarily due to growth from sales of AMVUTTRA driven by increased patient demand, partially offset by a decrease in sales of ONPATTRO due to patient switches to AMVUTTRA, as well as increased patients on GIVLAARI and OXLUMO therapies.

    Net Revenues from Collaborations

    • Net revenues from collaborations increased $30.5 million during the three months ended December 31, 2024, as compared to the same period in 2023, primarily due to the timing of manufacturing activities under our collaboration with Regeneron, as well as revenue recognized under our license agreement with Novartis associated with the achievement of specified commercialization milestones.
    • Net revenues from collaborations decreased by $36.0 million during the twelve months ended December 31, 2024, as compared to the same period in 2023, primarily due to differences in certain revenue items between 2023 and 2024. During 2023, we recognized $310.0 million of revenue from the upfront payment received from Roche in connection with execution of our zilebesiran collaboration. In comparison, during 2024, we recognized $185.0 million in revenues under our collaboration with Regeneron as we modified the collaboration in June 2024 and provided Regeneron with an exclusive license to develop, manufacture and commercialize cemdisiran as a monotherapy.

    Operating Expenses

     

    Three Months Ended

    December 31,

     

    Twelve Months Ended

    December 31,

    (In thousands)

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Cost of goods sold

    $

    102,649

     

     

    $

    71,975

     

     

    $

    306,513

     

     

    $

    268,216

     

    Cost of goods sold as a percentage of net product revenues

     

    22.8

    %

     

     

    20.8

    %

     

     

    18.6

    %

     

     

    21.6

    %

     

     

     

     

     

     

     

     

    Cost of collaborations and royalties

    $

    168

     

     

    $

    13,883

     

     

    $

    16,857

     

     

    $

    42,190

     

     

     

     

     

     

     

     

     

    GAAP Research and development expenses

    $

    300,169

     

     

    $

    272,141

     

     

    $

    1,126,232

     

     

    $

    1,004,415

     

    Non-GAAP Research and development expenses

    $

    259,544

     

     

    $

    253,056

     

     

    $

    998,483

     

     

    $

    907,142

     

     

     

     

     

     

     

     

     

    GAAP Selling, general and administrative expenses

    $

    295,339

     

     

    $

    198,123

     

     

    $

    975,526

     

     

    $

    795,646

     

    Non-GAAP Selling, general and administrative expenses

    $

    244,319

     

     

    $

    175,214

     

     

    $

    831,191

     

     

    $

    671,239

     

    Cost of Goods Sold

    • Cost of goods sold as a percentage of net product revenues increased during the three months ended December 31, 2024, as compared to the same period in the prior year, primarily due to higher royalty rates payable on net sales of AMVUTTRA.
    • Cost of goods sold as a percentage of net product revenues decreased during the twelve months ended December 31, 2024, as compared to the same period in the prior year. Approximately 5.0% of the 21.6% of cost of goods sold as a percentage of net product revenues for the year ended December 31, 2023 was attributable to cancelled manufacturing commitments and the impairment of ONPATTRO inventory that had been manufactured for future demand associated with the use of ONPATTRO for the treatment of patients with ATTR amyloidosis with cardiomyopathy, for which we did not receive regulatory approval in the U.S. These one-time charges in 2023 did not recur in 2024, resulting in the decrease in cost of goods sold as a percentage of net product revenues in 2024, which was partially offset by higher volume and royalty rates payable on net sales of AMVUTTRA in 2024.

    Research & Development (R&D) Expenses

    • GAAP and non-GAAP R&D expenses increased during the three and twelve months ended December 31, 2024, compared to the same periods in 2023, primarily due to increased costs associated with our preclinical activities as we develop our clinical pipeline of RNAi therapeutics targeting multiple tissues, increased clinical trial expenses associated with increased Phase 2 activities for the zilebesiran KARDIA-3 and mivelsiran cAPPRicorn-1 clinical trials, and increased employee compensation expenses. GAAP R&D expenses further increased during the three and twelve months ended December 31, 2024, compared to the same periods in 2023, due to higher stock-based compensation expense in 2024.

    Selling, General & Administrative (SG&A) Expenses

    • GAAP and non-GAAP SG&A expenses increased during the three and twelve months ended December 31, 2024, compared to the same periods in 2023, primarily due to higher costs associated with marketing investments to promote our TTR therapies and prepare for the potential launch of AMVUTTRA for the treatment of ATTR amyloidosis with cardiomyopathy and increased employee compensation expenses.

    Benefit from (provision for) income taxes

    • During the year ended December 31, 2024, we recorded a net benefit from income taxes of $99.2 million. This is primarily comprised of $106.8 million of foreign deferred benefit, partially offset by $1.6 million of domestic state current provision and $5.9 million of foreign current provision.

    Other Financial Highlights

    • Cash, cash equivalents and marketable securities were $2.69 billion as of December 31, 2024, as compared to $2.44 billion as of December 31, 2023, with the increase primarily due to improved operating performance and increased net proceeds from the issuance of common stock in connection with stock option exercises.

    A reconciliation of our GAAP to non-GAAP results for the three and twelve months ended December 31, 2024 and 2023, is included in the tables of this press release.

    2025 Financial Guidance

    Our full-year 2025 financial guidance is summarized below:

    Total TTR net product revenues (ONPATTRO, AMVUTTRA)1

    $1,600 million - $1,725 million

    Total Rare net product revenues (GIVLAARI, OXLUMO)

    $450 million - $525 million

    Total net product revenues

    $2,050 million - $2,250 million

    Net product revenues growth vs. 2024 at currency exchange rates as of December 31, 20242

    25% - 37%

    Net product revenues growth vs. 2024 at constant exchange rates3

    26% - 39%

    Net revenues from collaborations and royalties4

    $650 million - $750 million

    Non-GAAP R&D and SG&A expenses5

    $2,100 million - $2,200 million

    Non-GAAP Operating income5

    Achieve profitability

     

     

    1 Assumes U.S. sNDA approval of AMVUTTRA for ATTR-CM by the March 23, 2025 PDUFA action date and approvals and launches in Germany and Japan in the second half of 2025

    2 Full-year 2025 guidance utilizing currency exchange rates as of December 31, 2024: 1 EUR = 1.04 USD and 1 USD = 157 JPY

    3 Representing growth calculated as if the exchange rates had remained unchanged from those used in 2024, which is a non-GAAP financial measure

    4 Collaboration revenues assume achievement of $300 million milestone from Roche for initiation of a Phase 3 cardiovascular outcomes trial for zilebesiran. Royalty revenues assume approval of fitusiran by Sanofi by the March 28, 2025 PDUFA action date

    5 Primarily excludes $270-$330 million of stock-based compensation expense from estimated GAAP R&D and SG&A expenses

    Use of Non-GAAP Financial Measures

    This press release contains non-GAAP financial measures, including adjustments to exclude certain non-cash items and non-recurring transactions or events outside the ordinary course of the Company's business. These measures are not in accordance with, or an alternative to, GAAP, and may be different from non-GAAP financial measures used by other companies.

    The items included in GAAP presentations but excluded for purposes of determining non-GAAP financial measures for the periods presented in this press release are stock-based compensation expenses and realized and unrealized gains and losses on marketable equity securities. The Company has excluded the impact of stock-based compensation expense, which may fluctuate from period to period based on factors including the variability associated with performance-based grants for stock options and restricted stock units and changes in the Company's stock price, which impacts the fair value of these awards. The Company has excluded the impact of the realized and unrealized gains and losses on marketable equity securities because the Company does not believe these adjustments accurately reflect the performance of the Company's ongoing operations for the period in which such gains or losses are reported, as their sole purpose is to adjust amounts on the balance sheet.

    Percentage changes in revenue growth at CER are presented excluding the impact of changes in foreign currency exchange rates for investors to understand the underlying business performance. The current period's foreign currency revenue values are converted into U.S. dollars using the average exchange rates from the prior period.

    The Company believes the presentation of non-GAAP financial measures provides useful information to management and investors regarding the Company's financial condition and results of operations. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company's ongoing operating performance and are better able to compare the Company's performance between periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between GAAP and non-GAAP measures is provided later in this press release.

    Conference Call Information

    Management will provide an update on the Company and discuss fourth quarter and full year 2024 results as well as expectations for the future via conference call on Thursday, February 13, 2025 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event.

    About ONPATTRO® (patisiran)

    ONPATTRO is an RNAi therapeutic that is approved in the United States and Canada for the treatment of adults with hATTR amyloidosis with polyneuropathy. ONPATTRO is also approved in the European Union, Switzerland and Brazil for the treatment of hATTR amyloidosis in adults with Stage 1 or Stage 2 polyneuropathy, and in Japan for the treatment of hATTR amyloidosis with polyneuropathy. ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin (TTR). It is designed to target and silence TTR messenger RNA, thereby reducing the production of TTR protein before it is made. Reducing the pathogenic protein leads to a reduction in amyloid deposits in tissues. For more information about ONPATTRO, including full Prescribing Information, visit ONPATTRO.com.

    About AMVUTTRA® (vutrisiran)

    AMVUTTRA® (vutrisiran) is an RNAi therapeutic that delivers rapid knockdown of mutant and wild-type transthyretin (TTR), addressing the underlying cause of transthyretin (ATTR) amyloidosis. Administered quarterly via subcutaneous injection, AMVUTTRA is approved and marketed in more than 15 countries for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. Vutrisiran is also in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), which encompasses both wild-type and hereditary forms of the disease. For more information about AMVUTTRA, including the full U.S. Prescribing Information, visit AMVUTTRA.com.

    About GIVLAARI® (givosiran)

    GIVLAARI (givosiran) is an RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) approved in the United States and Brazil for the treatment of adults with acute hepatic porphyria (AHP). GIVLAARI is also approved in the European Union for the treatment of AHP in adults and adolescents aged 12 years and older. In the pivotal study, GIVLAARI was shown to significantly reduce the rate of porphyria attacks that required hospitalizations, urgent healthcare visits or intravenous hemin administration at home compared to placebo. GIVLAARI is Alnylam's first commercially available therapeutic based on its Enhanced Stabilization Chemistry ESC-GalNAc conjugate technology to increase potency and durability. GIVLAARI is administered via subcutaneous injection once monthly at a dose based on actual body weight and should be administered by a healthcare professional. GIVLAARI works by specifically reducing elevated levels of ALAS1 messenger RNA (mRNA), leading to reduction of toxins associated with attacks and other disease manifestations of AHP. For more information about GIVLAARI, including the full U.S. Prescribing Information, visit GIVLAARI.com.

    About OXLUMO® (lumasiran)

    OXLUMO (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1). HAO1 encodes glycolate oxidase (GO). Thus, by silencing HAO1 and depleting the GO enzyme, OXLUMO inhibits production of oxalate – the metabolite that directly contributes to the pathophysiology of PH1. OXLUMO utilizes Alnylam's Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate technology, which enables subcutaneous dosing with increased potency and durability and a wide therapeutic index. OXLUMO has received regulatory approvals from the U.S. Food and Drug Administration (FDA) for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients and from the European Medicines Agency (EMA) for the treatment of PH1 in all age groups. In the pivotal ILLUMINATE-A study, OXLUMO was shown to significantly reduce levels of urinary oxalate relative to placebo, with the majority of patients reaching normal or near-normal levels. In the ILLUMINATE-B pediatric Phase 3 study, OXLUMO demonstrated an efficacy and safety profile consistent to that observed in ILLUMINATE-A. In the ILLUMINATE-C study, OXLUMO resulted in substantial reductions in plasma oxalate in patients with advanced PH1. Across all three studies, injection site reactions (ISRs) were the most common drug-related adverse reaction. OXLUMO is administered via subcutaneous injection once monthly for three months, then once quarterly beginning one month after the last loading dose at a dose based on actual body weight. For patients who weigh less than 10 kg, ongoing dosing remains monthly. OXLUMO should be administered by a healthcare professional. For more information about OXLUMO, including the full U.S. Prescribing Information, visit OXLUMO.com.

    About LNP Technology

    Alnylam has licenses to Arbutus Biopharma lipid nanoparticle (LNP) intellectual property for use in RNAi therapeutic products using LNP technology.

    About RNAi

    RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today's medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This revolutionary approach has transformed the care of patients with genetic and other diseases.

    About Alnylam Pharmaceuticals

    Alnylam Pharmaceuticals (NASDAQ:ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines for people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran), which is being developed and commercialized by Alnylam's partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its "Alnylam P5x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on X (formerly Twitter) at @Alnylam, or on LinkedIn, Facebook, or Instagram.

    Alnylam Forward Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam's expectations, beliefs, goals, plans or prospects including, without limitation, statements regarding Alnylam's expectations regarding the potential approval and launch of AMVUTTRA for the treatment of ATTR amyloidosis with cardiomyopathy in the U.S. in early 2025 and in other countries later in 2025; Alnylam's advancement towards its "Alnylam P5x25" goals and positioning to deliver sustainable innovation to patients for the next half of the decade; the potential for Alnylam to advance its research and development programs, including the number of high-value programs Alnylam will have in the clinic by the end of 2025 and the timing of Alnylam's initiation of a Phase 3 clinical trial of nucresiran in ATTR-CM; the advancement of fitusiran through regulatory review and approval and Alnylam's receipt of any royalties on sales of fitusiran; and Alnylam's projected commercial and financial performance, including the expected range of net product revenues and net revenues from collaborations and royalties for 2025 and the expected range of aggregate annual GAAP and non-GAAP R&D and SG&A expenses for 2025, should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam's ability to successfully execute on its "Alnylam P5x25" strategy; Alnylam's ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam's product candidates, including vutrisiran, zilebesiran, nucresiran and mivelsiran; actions or advice of regulatory agencies and Alnylam's ability to obtain and maintain regulatory approval for its product candidates, including vutrisiran, as well as favorable pricing and reimbursement; successfully launching, marketing and selling Alnylam's approved products globally; delays, interruptions or failures in the manufacture and supply of Alnylam's product candidates or its marketed products; obtaining, maintaining and protecting intellectual property; Alnylam's ability to successfully expand the approved indications for AMVUTTRA in the future; Alnylam's ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile; Alnylam's ability to maintain strategic business collaborations; Alnylam's dependence on third parties for the development and commercialization of certain products, including Roche, Novartis, Sanofi, Regeneron and Vir; the outcome of litigation; the risk of future government investigations; and unexpected expenditures; as well as those risks and uncertainties more fully discussed in the "Risk Factors" filed with Alnylam's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

    This release discusses investigational RNAi therapeutics and uses of previously approved RNAi therapeutics in development and is not intended to convey conclusions about efficacy or safety as to those investigational therapeutics or uses. Vutrisiran has not been approved by any regulatory agency for the treatment of ATTR amyloidosis with cardiomyopathy. No conclusions can or should be drawn regarding its safety or effectiveness in treating cardiomyopathy in this population. There is no guarantee that any investigational therapeutics or expanded uses of commercial products will successfully complete clinical development or gain health authority approval.

     

    ALNYLAM PHARMACEUTICALS, INC.

    CONSOLIDATED BALANCE SHEETS

    (In thousands, except per share amounts)

     

     

    December 31,

    2024

     

    December 31,

    2023

    ASSETS

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    966,428

     

     

    $

    812,688

     

    Marketable debt securities

     

    1,719,920

     

     

     

    1,615,516

     

    Marketable equity securities

     

    8,156

     

     

     

    11,178

     

    Accounts receivable, net

     

    405,308

     

     

     

    327,787

     

    Inventory

     

    78,509

     

     

     

    89,146

     

    Prepaid expenses and other current assets

     

    116,964

     

     

     

    126,382

     

    Total current assets

     

    3,295,285

     

     

     

    2,982,697

     

    Property, plant and equipment, net

     

    502,784

     

     

     

    526,057

     

    Operating lease right-of-use assets

     

    191,148

     

     

     

    199,732

     

    Deferred tax assets

     

    116,863

     

     

     

    10,101

     

    Restricted investments

     

    68,593

     

     

     

    49,391

     

    Other assets

     

    65,310

     

     

     

    61,902

     

    Total assets

    $

    4,239,983

     

     

    $

    3,829,880

     

    LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    88,415

     

     

    $

    55,519

     

    Accrued expenses

     

    887,472

     

     

     

    713,013

     

    Operating lease liabilities

     

    41,886

     

     

     

    41,510

     

    Deferred revenue

     

    55,481

     

     

     

    102,753

     

    Liability related to the sale of future royalties

     

    113,018

     

     

     

    54,991

     

    Total current liabilities

     

    1,186,272

     

     

     

    967,786

     

    Operating lease liabilities, net of current portion

     

    229,541

     

     

     

    243,101

     

    Deferred revenue, net of current portion

     

    —

     

     

     

    188,175

     

    Convertible debt

     

    1,024,621

     

     

     

    1,020,776

     

    Liability related to the sale of future royalties, net of current portion

     

    1,334,353

     

     

     

    1,322,248

     

    Other liabilities

     

    398,108

     

     

     

    308,438

     

    Total liabilities

     

    4,172,895

     

     

     

    4,050,524

     

     

     

     

     

    Stockholders' equity (deficit):

     

     

     

    Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued

    and outstanding as of December 31, 2024 and December 31, 2023

     

    —

     

     

     

    —

     

    Common stock, $0.01 par value per share, 250,000 shares authorized as of December 31,

    2024 and December 31, 2023, respectively; 129,294 shares issued and outstanding as of

    December 31, 2024; 125,794 shares issued and outstanding as of December 31, 2023

     

    1,293

     

     

     

    1,259

     

    Additional paid-in capital

     

    7,388,061

     

     

     

    6,811,063

     

    Accumulated other comprehensive loss

     

    (34,518

    )

     

     

    (23,375

    )

    Accumulated deficit

     

    (7,287,748

    )

     

     

    (7,009,591

    )

    Total stockholders' equity (deficit)

     

    67,088

     

     

     

    (220,644

    )

    Total liabilities and stockholders' equity (deficit)

    $

    4,239,983

     

     

    $

    3,829,880

     

    This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alnylam's Annual Report on Form 10-K which includes the audited financial statements for the year ended December 31, 2024.

     

    ALNYLAM PHARMACEUTICALS, INC.

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (In thousands, except per share amounts)

     

     

    Three Months Ended

    December 31,

     

    Twelve Months Ended

    December 31,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

     

    (Unaudited)

     

    (Unaudited)

     

     

     

     

    Revenues:

     

     

     

     

     

     

     

    Net product revenues

    $

    450,831

     

     

    $

    346,288

     

     

    $

    1,646,228

     

     

    $

    1,241,474

     

    Net revenues from collaborations

     

    106,948

     

     

     

    76,407

     

     

     

    510,221

     

     

     

    546,185

     

    Royalty revenue

     

    35,387

     

     

     

    17,023

     

     

     

    91,794

     

     

     

    40,633

     

    Total revenues

     

    593,166

     

     

     

    439,718

     

     

     

    2,248,243

     

     

     

    1,828,292

     

     

     

     

     

     

     

     

     

    Operating costs and expenses:

     

     

     

     

     

     

     

    Cost of goods sold

     

    102,649

     

     

     

    71,975

     

     

     

    306,513

     

     

     

    268,216

     

    Cost of collaborations and royalties

     

    168

     

     

     

    13,883

     

     

     

    16,857

     

     

     

    42,190

     

    Research and development

     

    300,169

     

     

     

    272,141

     

     

     

    1,126,232

     

     

     

    1,004,415

     

    Selling, general and administrative

     

    295,339

     

     

     

    198,123

     

     

     

    975,526

     

     

     

    795,646

     

    Total operating costs and expenses

     

    698,325

     

     

     

    556,122

     

     

     

    2,425,128

     

     

     

    2,110,467

     

    Loss from operations

     

    (105,159

    )

     

     

    (116,404

    )

     

     

    (176,885

    )

     

     

    (282,175

    )

    Other (expense) income:

     

     

     

     

     

     

     

    Interest expense

     

    (38,971

    )

     

     

    (31,338

    )

     

     

    (141,858

    )

     

     

    (121,221

    )

    Interest income

     

    31,019

     

     

     

    30,406

     

     

     

    121,992

     

     

     

    95,561

     

    Other expense, net

     

    (80,847

    )

     

     

    (20,351

    )

     

     

    (180,624

    )

     

     

    (125,682

    )

    Total other expense, net

     

    (88,799

    )

     

     

    (21,283

    )

     

     

    (200,490

    )

     

     

    (151,342

    )

    Loss before income taxes

     

    (193,958

    )

     

     

    (137,687

    )

     

     

    (377,375

    )

     

     

    (433,517

    )

    Benefit from (provision for) income taxes

     

    110,195

     

     

     

    (183

    )

     

     

    99,218

     

     

     

    (6,725

    )

    Net loss

    $

    (83,763

    )

     

    $

    (137,870

    )

     

    $

    (278,157

    )

     

    $

    (440,242

    )

    Net loss per common share — basic and diluted

    $

    (0.65

    )

     

    $

    (1.10

    )

     

    $

    (2.18

    )

     

    $

    (3.52

    )

    Weighted-average common shares used to compute

    basic and diluted net loss per common share

     

    129,116

     

     

     

    125,613

     

     

     

    127,651

     

     

     

    124,906

     

     

    ALNYLAM PHARMACEUTICALS, INC.

    RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES

    (In thousands, except per share amounts)

    (Unaudited)

     

     

    Three Months Ended

    December 31,

     

    Twelve Months Ended

    December 31,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Reconciliation of GAAP to Non-GAAP research and development:

     

     

     

     

     

     

     

    GAAP Research and development expenses

    $

    300,169

     

     

    $

    272,141

     

     

    $

    1,126,232

     

     

    $

    1,004,415

     

    Less: Stock-based compensation expenses

     

    (40,625

    )

     

     

    (19,085

    )

     

     

    (127,749

    )

     

     

    (97,273

    )

    Non-GAAP Research and development expenses

    $

    259,544

     

     

    $

    253,056

     

     

    $

    998,483

     

     

    $

    907,142

     

     

     

     

     

     

     

     

     

    Reconciliation of GAAP to Non-GAAP selling, general and

    administrative:

     

     

     

     

     

     

     

    GAAP Selling, general and administrative expenses

    $

    295,339

     

     

    $

    198,123

     

     

    $

    975,526

     

     

    $

    795,646

     

    Less: Stock-based compensation expenses

     

    (51,020

    )

     

     

    (22,909

    )

     

     

    (144,335

    )

     

     

    (124,407

    )

    Non-GAAP Selling, general and administrative expenses

    $

    244,319

     

     

    $

    175,214

     

     

    $

    831,191

     

     

    $

    671,239

     

     

     

     

     

     

     

     

     

    Reconciliation of GAAP to Non-GAAP operating (loss) income:

     

     

     

     

     

     

     

    GAAP Loss from operations

    $

    (105,159

    )

     

    $

    (116,404

    )

     

    $

    (176,885

    )

     

    $

    (282,175

    )

    Add: Stock-based compensation expenses

     

    91,645

     

     

     

    41,994

     

     

     

    272,084

     

     

     

    221,680

     

    Non-GAAP Operating (loss) income

    $

    (13,514

    )

     

    $

    (74,410

    )

     

    $

    95,199

     

     

    $

    (60,495

    )

     

     

     

     

     

     

     

     

    Reconciliation of GAAP to Non-GAAP other expense, net:

     

     

     

     

     

     

     

    GAAP Total other expense, net

    $

    (88,799

    )

     

    $

    (21,283

    )

     

    $

    (200,490

    )

     

    $

    (151,342

    )

    Add (Less): Realized and unrealized losses (gains) on marketable equity

    securities

     

    166

     

     

     

    (767

    )

     

     

    3,022

     

     

     

    16,944

     

    Non-GAAP Other expense, net

    $

    (88,633

    )

     

    $

    (22,050

    )

     

    $

    (197,468

    )

     

    $

    (134,398

    )

     

     

     

     

     

     

     

     

    Reconciliation of GAAP to Non-GAAP net income (loss):

     

     

     

     

     

     

     

    GAAP Net loss

    $

    (83,763

    )

     

    $

    (137,870

    )

     

    $

    (278,157

    )

     

    $

    (440,242

    )

    Add: Stock-based compensation expenses

     

    91,645

     

     

     

    41,994

     

     

     

    272,084

     

     

     

    221,680

     

    Add (Less): Realized and unrealized losses (gains) on marketable equity

    securities

     

    166

     

     

     

    (767

    )

     

     

    3,022

     

     

     

    16,944

     

    Non-GAAP Net income (loss)

    $

    8,048

     

     

    $

    (96,643

    )

     

    $

    (3,051

    )

     

    $

    (201,618

    )

     

     

     

     

     

     

     

     

    Reconciliation of GAAP to Non-GAAP net loss per common share-basic

    and diluted:

     

     

     

     

     

     

     

    GAAP Net loss per common share - basic and diluted

    $

    (0.65

    )

     

    $

    (1.10

    )

     

    $

    (2.18

    )

     

    $

    (3.52

    )

    Add: Stock-based compensation expenses

     

    0.71

     

     

     

    0.33

     

     

     

    2.13

     

     

     

    1.77

     

    Add (Less): Realized and unrealized losses (gains) on marketable equity

    securities

     

    —

     

     

     

    (0.01

    )

     

     

    0.02

     

     

     

    0.14

     

    Non-GAAP Net loss per common share - basic and diluted

    $

    0.06

     

     

    $

    (0.77

    )

     

    $

    (0.02

    )

     

    $

    (1.61

    )

    Please note that the figures presented above may not sum exactly due to rounding

     

    ALNYLAM PHARMACEUTICALS, INC.

    RECONCILIATION OF GAAP TO NON-GAAP

    PRODUCT REVENUE GROWTH AT CONSTANT EXCHANGE RATE

     

     

    December 31, 2024

     

    Three Months

    Ended

     

    Twelve Months

    Ended

    Total TTR net product revenue growth*, as reported

    35

    %

     

    34

    %

    Add: Impact of foreign currency translation

    (1

    )

     

    —

     

    Total TTR net product revenue growth at constant exchange rate

    34

    %

     

    34

    %

     

     

     

     

    Total Rare net product revenue growth*, as reported

    18

    %

     

    29

    %

    Add: Impact of foreign currency translation

    (1

    )

     

    (1

    )

    Total Rare net product revenue growth at constant exchange rate

    17

    %

     

    28

    %

     

     

     

     

    Total net product revenue growth*, as reported

    30

    %

     

    33

    %

    Add: Impact of foreign currency translation

    (1

    )

     

    —

     

    Total net product revenue growth at constant exchange rate

    29

    %

     

    33

    %

     

     

     

     

    Total revenue growth*, as reported

    35

    %

     

    23

    %

    Add: Impact of foreign currency translation

    (1

    )

     

    —

     

    Total revenue growth at constant exchange rate

    34

    %

     

    23

    %

    *As compared to the three and twelve months ended December 31, 2023, respectively.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250213911700/en/

    Alnylam Pharmaceuticals, Inc.

    Christine Regan Lindenboom

    (Investors and Media)

    617-682-4340

    Josh Brodsky

    (Investors)

    617-551-8276

    Get the next $ALNY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ALNY

    DatePrice TargetRatingAnalyst
    3/31/2025$353.00Buy
    Redburn Atlantic
    3/24/2025$280.00 → $328.00Neutral → Overweight
    Analyst
    11/12/2024Peer Perform → Underperform
    Wolfe Research
    10/16/2024Sector Outperform
    Scotiabank
    8/16/2024$198.00 → $370.00Neutral → Buy
    Goldman
    2/16/2024$173.00Buy → Neutral
    Goldman
    2/15/2024Peer Perform
    Wolfe Research
    12/8/2023$171.00Equal Weight
    Wells Fargo
    More analyst ratings

    $ALNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Redburn Atlantic initiated coverage on Alnylam Pharma with a new price target

      Redburn Atlantic initiated coverage of Alnylam Pharma with a rating of Buy and set a new price target of $353.00

      3/31/25 8:12:33 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam Pharma upgraded by Analyst with a new price target

      Analyst upgraded Alnylam Pharma from Neutral to Overweight and set a new price target of $328.00 from $280.00 previously

      3/24/25 8:23:59 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam Pharma downgraded by Wolfe Research

      Wolfe Research downgraded Alnylam Pharma from Peer Perform to Underperform

      11/12/24 7:27:31 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for GIVLAARI issued to ALNYLAM PHARMS INC

      Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-7) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 04/29/2024. Application Category: NDA, Application Number: 212194, Application Classification: Labeling

      4/30/24 1:44:03 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for OXLUMO issued to ALNYLAM PHARMS INC

      Submission status for ALNYLAM PHARMS INC's drug OXLUMO (SUPPL-4) with active ingredient LUMASIRAN SODIUM has changed to 'Approval' on 09/19/2023. Application Category: NDA, Application Number: 214103, Application Classification: Labeling

      9/20/23 2:36:38 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for AMVUTTRA issued to ALNYLAM PHARMS INC

      Submission status for ALNYLAM PHARMS INC's drug AMVUTTRA (SUPPL-2) with active ingredient VUTRISIRAN has changed to 'Approval' on 02/16/2023. Application Category: NDA, Application Number: 215515, Application Classification: Labeling

      2/17/23 12:30:09 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CSO & EVP, Head of Research Fitzgerald Kevin Joseph was granted 7,763 shares, increasing direct ownership by 57% to 21,264 units (SEC Form 4)

      4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

      7/2/25 4:26:48 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Greenstreet Yvonne exercised 50,937 shares at a strike of $118.56 and sold $15,535,784 worth of shares (50,937 units at $305.00) (SEC Form 4)

      4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

      6/3/25 4:10:42 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bonney Michael W exercised 11,250 shares at a strike of $131.21 and sold $3,124,217 worth of shares (11,250 units at $277.71) (SEC Form 4)

      4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

      5/19/25 4:17:09 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNY
    SEC Filings

    See more
    • Alnylam Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

      6/18/25 4:48:38 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

      5/13/25 5:01:36 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Alnylam Pharmaceuticals Inc.

      10-Q - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

      5/1/25 8:15:07 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients

      OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease1 MISSISSAUGA, ON, July 2, 2025 /CNW/ - Alnylam Canada ULC is pleased to announce that OXLUMO® (lumasiran) is now funded across Canada through both public and private plans. OXLUMO is an RNA interference (RNAi) therapeutic administered via subcutaneous injection, indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in paediatric and adult patients.1 OXLUMO is the first therapy for PH1 approved in Canada, and among the first medi

      7/2/25 12:30:00 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer

      − R&D Organization Positioned to Deliver Next Wave of Transformative RNAi Therapeutics – − Goal of Delivering RNAi Therapeutics to All Major Tissues by 2030 – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed Executive Vice President, Chief Research and Development Officer to oversee an integrated R&D organization. Building on the launch of AMVUTTRA® in transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Alnylam is entering a new phase of growth, and a combined R&D organization will accelerate pipeline progress by fostering earlier collaboration, faster decision-making,

      6/18/25 10:05:00 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

      DALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the addition of John Maraganore, Ph.D., to the Board of Directors of Axion Bio, Inc., Instil's wholly-owned subsidiary dedicated to the development of AXN-2510 ("'2510"), a potentially best-in-class PD-L1xVEGF bispecific antibody for solid tumors prioritizing front-line non-small cell lung cancer (NSCLC). "John's appointment reflects our commitment to assembling world-class leadership to maximize the value of the ‘2510 program for patients and shareholders, and we have benefited greatly fr

      6/11/25 7:00:22 AM ET
      $ALNY
      $TIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $ALNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Reitan Colleen F bought $10,363 worth of shares (36 units at $287.85), sold $8,383 worth of shares (36 units at $232.86) and was granted 775 shares (SEC Form 4)

      4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

      5/12/25 4:05:00 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

      SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

      11/12/24 9:50:12 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

      SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

      11/8/24 10:34:33 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

      SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

      8/12/24 9:40:06 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNY
    Leadership Updates

    Live Leadership Updates

    See more
    • Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

      Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company's Board of Directors, effective as of May 8, 2025. Dr. Sharp has served as a key advisor to Alnylam since he co-founded the Company in 2002. Dr. Sharp will remain a member of the Alnylam Scientific Advisory Board. "Phil helped pioneer the RNAi revolution, sparking the scientific collaboration that led to Alnylam's founding and the development of a transformative new class of medicines," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "He has provided invaluable guidance over the past twenty-two years that has

      3/5/25 7:00:00 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ByHeart Appoints Amy Schulman as Chair of the Board of Directors, Further Solidifying its Position as a Leader in the Infant Nutrition Category

      As former leader of Pfizer's infant nutrition and consumer healthcare businesses, Schulman brings extensive experience in the space, in addition to serving on the boards of several biotech and pharmaceutical companies; This marks ByHeart's first non-executive Board chair appointment In addition to Schulman, ByHeart appoints Niall Mullane, PhD, as Chief Quality Officer to join the experienced executive team; Mullane brings 15 years of quality and food safety experience in the infant nutrition category NEW YORK, March 5, 2024 /PRNewswire/ --Today, ByHeart, the next-generation baby nutrition company, announced the appointment of Amy Schulman, managing partner at Polaris partners, as Chair of th

      3/5/24 9:06:00 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam Announces Appointment of Peter Kellogg to Board of Directors

      – Experienced Business and Financial Leader, Kellogg Served as Chief Financial Officer at Biogen, Merck, and Celgene – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic management experience. "Mr. Kellogg joins our Board at a pivotal moment for Alnylam as we continue on the path to achieving our P5x25 strategy and fulfilling our ambition to become a top-tier biopharmaceutical company," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "His financial expertise and experi

      3/8/23 7:00:00 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNY
    Financials

    Live finance-specific insights

    See more
    • Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

      − Achieved First Quarter 2025 Global Net Product Revenues of $469 Million, Representing 28% Year-Over-Year Growth Compared to Q1 2024 Driven by Continued Strong Growth of 36% from hATTR-PN Franchise – − Received U.S. Food and Drug Administration (FDA) Approval of AMVUTTRA® (vutrisiran) to Reduce Cardiovascular Death, Cardiovascular Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) – − AMVUTTRA ATTR-CM Launch Underway with Strong Progress Across All Early Commercial Indicators – − Approval of Qfitlia™ Represents the First and Only Therapeutic to Treat Hemophilia A or B With or Without Inhibitors and the Sixth Alnylam-Discovered

      5/1/25 8:00:00 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results

      Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May 1, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2025 results as well as expectations for the future via conference call on Thursday, May 1, 2025 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event. About Alnylam Pharmaceuticals A

      4/17/25 8:00:00 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

      − Novel Mechanism of Action Delivers Rapid Knockdown of Transthyretin, Addressing the Disease at its Source – − Proven Consistency of Effect on Cardiovascular Outcomes, Function, and Quality of Life in ATTR-CM Population Representative of Today's Patients – – Only Therapeutic Approved in the U.S. to Address Both Cardiomyopathy and Polyneuropathy Manifestations of ATTR Amyloidosis − – Alnylam Offers Multiple Programs to Support Broad and Seamless Patient Access; Majority of Patients Expected to Pay $0 in Out-of-Pocket Costs for AMVUTTRA – – Alnylam to Host Conference Call Today at 6:00 pm ET – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today anno

      3/20/25 5:54:00 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care